Background: Testicular germ cell tumors (TGCTs) belong to the most chemosensitive solid tumors; however, a small proportion of patients fail to be cured with cisplatin-based chemotherapy. Inhibitors of PD-1/PD-L1 pathways represent a new class of promising drugs in anticancer therapy. The aim of this study was to evaluate expression and prognostic value of PD-1 and PD-L1 in TGCTs.
introduction Testicular germ cell tumors (TGCTs) belong to the most chemosensitive solid tumors and are the most common type of cancer in men between 20 and 40 years of age [1] . Cisplatinbased chemotherapy is the mainstay in the treatment of TGCTs and ∼70%-80% of the patients with disseminated testicular cancer can be cured with this treatment, although 20%-30% of the patients do not respond, or relapse [2, 3] . Salvage chemotherapy based on the standard cisplatin dose and previously non-utilized drugs may cure ∼20%-25% of patients with relapsed TGCTs [3] [4] [5] . Because of insufficient results in the treatment of relapsed TGCTs, evaluation of new treatment strategies and novel drugs with significant antitumor activity, as a single-agent or combination, is a priority [6] .
One of the new promising targets in different types of tumors is programmed-death-1 receptor (PD-1; CD279) and its ligand (PD-L1; B7-H1; CD274), which deliver inhibitory signals that regulate the balance between T-cell activation, tolerance and immune-mediated tissue damage [7] . PD-1 is a member of the immunoglobulin superfamily and is expressed on double-negative T cells in thymus and on activated CD4 + T cells, CD8 + T cells, natural killer cells, B cells and monocytes [8] . It is primarily involved in modulating T-cell activity in peripheral tissues through interaction with its ligands PD-L1 and PD-L2 [9] . PD-L1 is expressed in different organs, including the placenta, heart, lung and liver as well as on activated T cells, B cells, dendritic cells, macrophages and mesenchymal stem cells [10] .
PD-L1 is expressed also on various tumor cells [8] . Expression of PD-L1 is an important process by which tumor cells suppress antitumor immunity in the tumor microenvironment [11] . The prognostic significance of PD-L1 expression on tumor cells was described in various malignancies, including non-small-cell lung cancer [12, 13] , malignant melanoma [13, 14] , renal cell carcinoma [13, 15] , colorectal [16] and breast cancer [17] . The inhibition of PD-1/PD-L1 interaction is becoming a promising area in cancer treatment. PD-1 and PD-L1 blocking antibodies have demonstrated clinical activity in several types of cancer, including melanoma, non-small-cell lung cancer, renal cell cancer, ovarian cancer and head and neck cancers [18] .
Recent data suggest that PD-L1 is overexpressed in TGCTs, including 73% seminomas and 64% non-seminomatous tumors, but none of normal testicular tissue specimens exhibited PD-L1 expression [19] . Therefore, PD-1/PD-L1 could be promising novel therapeutic targets in TGCTs [19] . The prognostic value of PD-1 and PD-L1 expression and their association with patients' tumor characteristics has not been reported. The aim of this translational study was to evaluate expression of PD-1 and PD-L1 and to assess its prognostic role in patients with TGCTs.
patients and methods

study patients
Into this translational study (Protocol IZLO1, Chair: M. Mego) were included 140 patients with TGCT treated from January 1999 to December 2013 in the National Cancer Institute and St Elisabeth Cancer Institute in Slovakia, with available paraffin-embedded tumor tissue specimen and sufficient follow-up clinical data. Patients with concurrent malignancy other than non-melanoma skin cancer in the previous 5 years were excluded. In all patients, data regarding age, tumor histology, clinical stage, type and number of metastatic sites, and delivery of systemic therapy were recorded and compared with PD-L1 expression. The Institutional Review Board approved this retrospective study and a waiver of consent from patients was granted.
tumor pathology
Pathology review was conducted at the Department of Pathology, Faculty of Medicine, Comenius University, by two pathologists (ZC and PB) associated with the study.
diagnosis and tissue samples
Tumor tissue and normal testicular tissue were evaluated in all cases, when available. The study included tumor specimens from 140 patients before administration of systemic therapy. All but nine of these specimens were obtained from primary testicular tumors. Biopsies of abdominal and mediastinal masses were carried out in seven and in two cases of extragonadal primitive tumors, respectively. The TGCTs were classified according to World Health Organization criteria [20] . Normal testicular tissue from noncancer patients was not available for analysis; therefore, we used normal tissue adjacent to testicular tumor for PD-1 and PD-L1 expression evaluation, as described in previous studies [21] [22] [23] .
tissue microarray construction
According to tumor histology, one or two representative tumor areas from each histological subtype of germ cell tumor were identified on H&E sections. Samples from normal testicular tissue were also marked, if present. Tissue microarray was constructed as described previously [22] .
immunohistochemical staining
Slides were deparaffinized and rehydrated in phosphate-buffered saline solution (10 mM, pH 7.2). The tissue epitopes were demasked using the automated water-bath heating process in Dako PT Link (Dako, Glostrup, Denmark); the slides were incubated in TRIS-EDTA retrieval solution (10 mM TRIS, 1 mM EDTA pH 9.0) at 98°C for 20 min. The slides were subsequently incubated for 1 h at room temperature with the primary mouse monoclonal antibody against PD-1 [Abcam (NAT105): AB52587] and rabbit monoclonal antibody against PD-L1 {Abcam [EPR1161(2)]: AB174838} diluted 1 : 100 in Dako REAL antibody diluent (Dako) and immunostained using anti-mouse/anti-rabbit immuno-peroxidase polymer (EnVision FLEX/ HRP, Dako) for 30 min at room temperature, according to the manufacturer's instructions. Color reaction was developed with diaminobenzidine substratechromogen solution (DAB, Dako) for 5 min. Finally, the slides were counterstained with hematoxylin and mounted. PD-1 and PD-L1 positivity of lymphocytes in the tonsil was used as a positive control, same tissue with omitting of the primary antibody served as negative control.
immunohistochemical stain scoring
Tumor cores were independently assessed by two observers (ZC and PB) who were blinded to clinicopathological data. In cases of disagreement, the result was reached by consensus. PD-1 and PD-L1 expressions were scored by the multiplicative quickscore (QS) method, which accounts for both the extent of cell staining and staining intensity as we described previously [22] . Based on the QS, membranous or cytoplasmic PD-1 and PD-L1 expressions were graded as low (0-9) or high (10) (11) (12) (13) (14) (15) (16) (17) (18) .
statistics
The distribution of the PD-1 and PD-L1 QS was significantly different from the normal distribution (Shapiro-Wilk's test); therefore, we used non-parametric tests for analyses. Analyses of differences in distributions of PD-1 and PD-L1 expression between the two groups of patients were carried out using the Mann-Whitney U-test, while Fisher's exact test or the χ 2 test when appropriate were used, when PD-1 and PD-L1 expression was categorized as 'low' or 'high' according to the aforementioned criteria. The median follow-up period was calculated as a median observation time among all patients and among those still alive at the time of their last follow-up. Progression-free survival (PFS) was calculated from the date of orchiectomy or the date of tumor biopsy to the date of progression or death or the date of last adequate follow-up. Overall survival (OS) was calculated from the date of orchiectomy or date of tumor biopsy to the date of death or last follow-up. PFS and OS were estimated using the Kaplan-Meier product limit method and compared by the log-rank test. A multivariate Cox proportional hazards model for PFS and OS was used to assess differences in outcome on the basis of PD-L1 expression in primary tumor and prognosis according to IGCCCG (International Germ Cell Collaborative Group) [24] . Table S2 , available at Annals of Oncology online). Six cases of seminomas were clinically considered as non-seminomas based on positivity of α-fetoprotein. Normal testicular tissue was available in 28 cases.
We did not detect expression of PD-1 in any of tumor specimens (supplementary Figure S3 , available at Annals of Oncology online). In contrast to PD-1, PD-L1 expression was found in 76% of seminomas and 89% of non-seminomas. PD-L1 expression in all germ cell tumors was significantly higher in comparison with normal testicular tissue [mean QS ± standard error of the mean (SEM) = 5.29 ± 0.42 versus 0.32 ± 0.16, P < 0.0001] ( Table 1 , supplementary Figure S3 , available at Annals of Oncology online). The highest PD-L1 expression was found in choriocarcinomas, with decreasing positivity in embryonal carcinoma, teratoma, yolk sac tumor and the lowest expression in seminoma. When we evaluated dichotomized PD-L1 expression, only 20% of TGCTs had high PD-L1 expression (QS ≥ 10), while none of the normal testicular tissue exhibit high PD-L1 expression. Embryonal carcinoma had significantly higher expression compared with seminoma and yolk sac tumors (P < 0.01), while choriocarcinomas had significantly higher PD-L1 overexpression when compared with all other histological subtypes (P < 0.001) ( Table 1) . Table 2 shows exploratory analysis of association between patients/tumor characteristics and PD-L1 expression in primary tumor. PD-L1 was significantly higher in non-seminomatous tumors in comparison with seminomas. Higher levels of PD-L1 were present in patients with more advanced disease, including patients with ≥3 metastatic sites, increased serum tumor markers, liver or other non-pulmonary visceral metastases. Primary mediastinal germ cell tumors were present only in two patients; however, these tumors had lower (mean QS ± SEM = 3.50 ± 3.57) PD-L1 expression than testicular primary tumor (5.35 ± 0.44) or primary retroperitoneal GCTs (4.57 ± 1.27); however, these differences were not statistically significant. The median followup time was 81.1 (0.3-235.8) months for all patients and 96.2 (21.0-235.8) months for patients still alive. During follow-up, 39 (27.9%) patients experienced disease progression and 28 (20.0%) patients died. All observed deaths were due to testicular cancer. The estimated 5-year PFS and OS was 72.6% [95% confidence interval (CI) 65.2%-80.1%] and 81.2% (95% CI 74.6%-87.7%), respectively. Patients with low PD-L1 (QS < 10) expression in primary tumor had significantly better PFS when compared with those with high PD-L1 (QS ≥ 10) expression [hazard ratio (HR) = 0.40, 95% CI 0.16-1.01, P = 0.0081] ( Figure 1A ). Similarly, patients with low PD-L1 had significantly better OS than those with high PD-L1 (HR = 0.43, 95% CI 0.15-1.23, P = 0.0397) ( Figure 1B) . In multivariate analysis, PD-L1 expression in primary tumor was associated with PFS independently of the IGCCCG risk group, but not with OS (Table 3) .
discussion
In this translational study, we showed lack of PD-1 expression and higher PD-L1 expression in TGCTs when compared with normal testicular tissue, which is consistent with previously reported data [19] . Moreover, we demonstrated for the first time the prognostic value of PD-L1 expression on PFS and OS. We observed the highest PD-L1 expression in choriocarcinomas that is consistent with the previous study and was congruent with the observed high expression of PD-L1 in normal placenta [8] , the tissue histologically related to choriocarcinoma. In contrast to the study by Fankhauser et al. [19] , we observed lower level of PD-L1 expression in seminoma and embryonal carcinoma and higher in teratoma; however, due to different scoring systems and different utilized antibody for PD-L1 detection, the cross-trial comparison is difficult. We speculate that higher PD-L1 positivity in non-seminomas in our study might be related to worse prognosis; unfortunately, patients outcome was not reported in previous study [19] . Our data suggest association of higher PD-L1 expression with poor prognostic features, including non-seminomatous histology, increased number of metastatic sites, high serum tumor markers, presence of liver and/or other non-pulmonary visceral metastases. Numerically, PD-L1 expression correlated with TGCTs prognostic group according to IGCCCG, retroperitoneal and lung, but not mediastinal metastases. This suggests that immune tolerance mediated by increased PD-L1 expression in primary TGCTs facilitate tumor dissemination and could impair treatment response as well. We suppose that due to correlation between PD-L1 expression and some of the prognostic factors that classify patients within to the IGCCCG risk group, PD-L1 was not completely independently correlated with OS in multivariate analysis. Testis is a very interesting tissue from the immunologic point of view. It belongs to immunologically privileged sites, which means, that this tissue has naturally suppressed immune responses [25] . Sperm maturation occurs at puberty, after immune tolerance had been established; therefore, the immune system recognizes spermatids as foreign. Therefore, to prevent autoimmune reaction, there are several mechanisms for their protection. Previously, Cheng et al. revealed that one of the mechanism that contribute to immune privilege of testis is PD-1:PD-L1 negative co-stimulation. In that study, the authors showed that PD-L1 is constitutively expressed mainly by spermatocytes and spermatids in seminiferous tubules of the testis [25] . This contributes to the suppression of T-cell proliferation mediated by testicular immune privilege and plays a role in the suppression in the CD8+ cell memory generation and increased T-cell-induced apoptosis in testis. Their study provided first evidence that PD-L1 plays a role in testicular immune privilege that fosters long-term allograft survival [25] . Interaction of PD-1 with its ligands during infection and inflammation in normal tissues is important for maintaining homeostasis of immune response to prevent autoimmunity; however, this ligation in tumor microenvironments provides an immune escape for tumor cells by turning off cytotoxic T cells [13] . In our study, opposite to the study by Cheng et al., but consistent with the data presented by Fankhauser et al, we failed to detect constitutive expression of PD-L1 in normal testicular tissue [19, 25] . We observed that primary mediastinal GCTs had lower PD-L1 expression in comparison with primary testicular tumors. We speculate that immune privilege of testis partially mediated by PD-L1 is probably involved in the pathogenesis of primary testicular but not mediastinal tumors; however, small number of extragonadal tumors in this study preclude definitive conclusion.
The study has some limitations, including the retrospective nature of the analysis and the relative under-representation of choriocarcinoma, yolk sac tumor and/or extragonadal germ cell tumors. The PD-L1 expression in TGCTs was correlated with the level of expression in the normal testicular tissue adjacent to the tumor. We recognize that the normally appearing tissue next to testicular tumor could be theoretically affected by the tumor or be preneoplastic or harbor preneoplastic cells. However, we observed higher PD-L1 expression in GCTs if compared with normal tissue; this would probably not be the case if normal tissue contained occult tumor cells or preneoplastic lesions. Moreover, all tissues considered to be normal were OCT3/4 negative. Despite that, we need to take into consideration this limitation in interpreting the study results.
In conclusion, in this translational study, we showed lack of PD-1 expression but significantly higher expression of PD-L1 in TGCTs when compared with normal testicular tissue. We showed for the first time correlation between higher PD-L1 expression in primary tumor tissue and inferior outcome in patients with TGCTs. PD-L1 expression is higher in patients with more advanced disease with poor prognostic features, suggesting that immune tolerance mediated by increased PD-L1 expression in primary TGCTs might facilitate tumor dissemination. Based on these data, we suggest that PD-L1 could be a novel promising therapeutic target in TGCTs. Further research is needed to determine whether PD-L1 is only a prognostic factor or also a predictive factor for tailoring anti-PD-1/PD-L1 therapy in TGCTs. 
